Following the company’s Q4 results and business update, H.C. Wainwright analyst Vernon Bernardino continues to believe a “strong investment thesis remains” for buying Novavax shares. The Prepare trial showed ResVax was safe, and importantly, resulted in clinically meaningful outcomes, Bernardino tells investors in a research note. While the stock remains down 76% from its closing price of $2.13 prior to the Prepare results, prospects for discussions with the FDA and European Medicines Agency, which are expected in the next 90 days, are positive, contends the analyst. He believe ResVax’s pathway to approval is “under-appreciated” and would be a buyer of the stock. Bernardino keeps a Buy rating on Novavax with a $2.00 price target. The stock in midday trading is down fractionally at 52c.